Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 12/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.49 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27931266 | 0.85 | MTNR1A (0.51) | MTNR1AMTNR1BPARP1HSD17B2HSD17B1 | |
| SCHEMBL28103467 | 0.84 | HSD17B2 (0.55) | MTNR1AMTNR1BPARP1HSD17B2HSD17B1 | |
| SCHEMBL1144595 | 0.83 | MTNR1A (0.50) | MTNR1AMTNR1BPARP1HSD17B2HSD17B1 | |
| SCHEMBL22251760 | 0.82 | MTNR1A (0.49) | MTNR1AMTNR1BPARP1HSD17B2HSD17B1 | |
| SCHEMBL7998902 | 0.82 | ALDH1A1 (0.44) | LMNANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL28088974 | 0.81 | MTNR1A (0.48) | MTNR1AMTNR1BPARP1HSD17B2HSD17B1 | |
| SCHEMBL20264517 | 0.81 | HSD17B2 (0.61) | MTNR1AMTNR1BHSD17B2HSD17B1CES2 | |
| SCHEMBL3635559 | 0.80 | MTNR1A (0.52) | MTNR1AMTNR1BHSD17B2HSD17B1 | |
| SCHEMBL4288276 | 0.80 | PARP1 (0.44) | MTNR1AMTNR1BPARP1HSD17B2HSD17B1 | |
| SCHEMBL1012749 | 0.79 | MTNR1A (0.51) | MTNR1AMTNR1BPARP1HSD17B2HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1971596-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | Takeda Pharmaceutical Company Limited (JP) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007077961-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | MTNR1A 369/4885MTNR1B 347/4885PARP1 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.